Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00161
2008-03-31
Prospective
Nil
Department of Paediatrics, CUHK
Department of Paediatrics, CUHK
N/A
Lam, Hugh Simon Hung San
Department of Paediatrics, 6/F Clinical Sciences Building, PWH
26322211
hshslam@cuhk.edu.hk
The Chinese University of Hong Kong
Lam, Hugh Simon Hung San
Department of Paediatrics, 6/F Clinical Sciences Building, PWH
26322211
hshslam@cuhk.edu.hk
The Chinese University of Hong Kong
A randomised, double-blind, controlled study of Omegaven for rescue treatment of parenteral nutrition-associated cholestasis (PNAC) in infants requiring long-term parenteral nutrition
A randomised, double-blind, controlled study of Omegaven for rescue treatment of parenteral nutrition-associated cholestasis (PNAC) in infants requiring long-term parenteral nutrition
Treatment infant parenteral lipid study
Hong Kong SAR, China
Yes
2008-02-06
Parenteral nutrition-associated cholestasis in infants
Other
parenteral lipid supplement
Omegaven (fish oil-based parenteral lipid supplement)
For as long as subject requires parenteral nutrition (may be 4 months or more)
Intralipid (soy-based parenteral lipid supplement)
Inclusion criteria: (i) developed PNAC, defined as serum conjugated bilirubin concentration ≥ 34 mmol/L on routine weekly liver function assessment, in patients on parental nutrition
(ii) expected to receive at least two more weeks of parenteral nutrition
(iii) informed parental consent
(i) major congenital or lethal chromosomal abnormalities
(ii) multiorgan failure and imminent death
(iii) cholestatic jaundice secondary to other known causes e.g., congenital or acquired TORCH and syphillis infection; hepatitis B and C infection; biliary atresia and other lesions obstructing bile flow, both intrahepatic and extrahepatic
0 days
12 months
Both Male and Female
Interventional
Randomized
Active
Double-blind
Parallel
2008-04-30
54
Recruiting
Reversal of PNAC over 4 months
Infant growth; blood lipid profile; coagulation status; episodes of late-onset infection over 4 months.
2013-04-05
Yes
N/A
|
|
|
|
|
---|---|---|---|---|
No documents yet. |